

1 **Antibody response to *Plasmodium vivax* in the context of Epstein-Barr virus**
2 **(EBV) co-infection: A 14-year follow-up study in the Amazon rainforest**

3

4 Luiz F. F. Guimarães¹, Bárbara A. Rodrigues¹, Michelle H. F. Dias¹, Matheus G. Barcelos²,
5 Maria F. A. Nascimento¹, Sâmick L. Moreira-Nascimento¹, Sofia L. Afonso¹, Barbara G. S. Abreu¹,
6 Jaap. M. Middeldorp³, Francis B. Ntumngia⁴, John H. Adams⁴, Camila Fabbri^{5,6}, Stefanie Lopes^{5,6},
7 Cor J. F. Fernandes⁷, Flora S. Kano¹, Luzia H. Carvalho^{1*}

8

9 ¹ Instituto René Rachou, Fiocruz Minas, Fundação Oswaldo Cruz (Fiocruz), Belo Horizonte,
10 Minas Gerais, Brazil

11 ² Laboratório de vírus, Departamento de Microbiologia, Instituto de Ciências Biológicas,
12 Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Minas Gerais, Brazil

13 ³ Department of Pathology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands.

14 ⁴ Center for Global Health and Interdisciplinary Disease Research, College of Public Health,
15 University of South Florida, Tampa, Florida, United States

16 ⁵ Instituto Leônidas & Maria Deane, Fiocruz Amazônia, Fundação Oswaldo Cruz, Manaus,
17 Amazonas, Brazil

18 ⁶ Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Unidade de Pesquisa Clínica
19 Carlos Borborema, Manaus, Amazonas, Brazil

20 ⁷ Hospital Universitário Julio Müller, Faculdade de Medicina, Universidade Federal de Mato
21 Grosso (UFMT), Cuiabá, Mato Grosso, Brazil

22

23 *Corresponding author

24 E-mail: luzia.carvalho@fiocruz.br (LHC)

25

26

27 **Abstract**

28 **Background:** To develop an effective vaccine against *Plasmodium vivax*, the most widely
29 dispersed human malaria parasite, it is critical to understand how coinfections with other pathogens
30 could impact malaria-specific immune response. A recent conceptual study proposed that Epstein-
31 Barr virus (EBV), a highly prevalent human herpesvirus that establishes lifelong persistent
32 infection, may influence *P. vivax* antibody responses. Here, it was investigated whether EBV could
33 impact the longevity of humoral immune response to *P. vivax*.

34 **Methodology/principal findings:** A 14-year follow-up study was carried out among long-
35 term *P. vivax*-exposed Amazonian individuals (272, median age 35 years), and included 9 cross-
36 sectional surveys at periods of high and low malaria transmission. The experimental approach
37 focused on monitoring antibodies to the major blood-stage *P. vivax* vaccine candidate, the Duffy
38 binding protein region II (DBPII-Sal1), including a novel engineered DBPII-based vaccine targeting
39 conserved epitopes (DEKnull-2). In parallel, the status of EBV infection was determined over time
40 by the detection of circulating EBV DNA (EBV-DNAemia) and EBV-specific antibodies to lytic
41 (VCAP18) or latent (EBNA1) antigens. Regardless of the malaria transmission period, the results
42 demonstrated that one or multiple episodes of EBV-DNAemia did not influence the longevity of
43 DBPII immune responses to both strain-specific (Sal-1) or strain-transcending (DEKnull-2)
44 antibodies. Also, the average time in which DBPII-responders lost their antibodies was unrelated to
45 the EBV serostatus. Considering all malaria cases detected during the study, there was a
46 predominance of *P. vivax* mono-infection (76%), with a positive association between malaria
47 infection and detectable EBV-DNAemia.

48 **Conclusions/significance:** In an immunocompetent *P. vivax*-exposed adult population
49 neither sporadic episodes of EBV-DNAemia nor antibody responses to lytic/latent EBV antigens
50 influence the longevity of both strain-specific and strain-transcending DBPII immune responses.
51 Further studies should investigate the role of acute *P. vivax* infection in the activation of EBV
52 replication cycle.

53

54 **Introduction**

55 Despite the decline in the global burden of malaria, the progress towards disease control has
56 stagnated in recent years, underscoring the fragility of hard-won gains against malaria [1]. In the
57 case of *Plasmodium vivax*, the most widespread human malaria parasite, plateauing gains and areas
58 with an increased burden highlight the fact that the challenges on the road to malaria elimination are
59 greater than expected [2]. Key discoveries in *P. vivax* biology, including an endosplenic life cycle
60 associated with recurrent chronic infections, pose additional challenges to control and elimination
61 of the parasite [3, 4]. Concurring, the proportion of malaria caused by *P. vivax* has been increasing
62 in co-endemic regions where intensive malaria-control activities have successfully reduced the
63 incidence of *P. falciparum* [5].

64 Although under investigated, *P. vivax* in a scenario of co-infection with viruses commonly
65 circulating in endemic areas can worsen the impact of these diseases on public health, reducing the
66 effectiveness of therapeutic and prophylactic measures [6-11]. With continuing interest in the
67 elimination of *P. vivax* infections, and to the development of an effective vaccine against this
68 parasite, it is necessary to understand how viral infections could impact the immune response
69 induced by potential vaccine candidates. Particularly, because there are only a few *P. vivax* vaccines
70 in clinical trials [12].

71 In experimental models, it has been proposed that gamma herpesvirus co-infection with
72 malaria may suppress anti-parasitic humoral immunity [13]. Given that the B-cell compartment is
73 the primary niche for Epstein-Barr virus (EBV), a highly prevalent human gamma herpes virus [14],
74 it is plausible to speculate that the humoral immune response to malaria may be altered during EBV
75 co-infection [13]. In a conceptual case-control study, we provided evidence that antibody levels
76 against major *P. vivax* vaccine candidates were generally lower in malaria-exposed individuals
77 whose viral DNA was persistently detected in the peripheral blood [15]. To further investigate
78 whether EBV could impact the long-term humoral immune response to *P. vivax*, we took advantage

79 of a 14-year follow-up study among individuals exposed to malaria in the Amazon rainforest,
80 focusing on a major blood-stage *P. vivax* vaccine candidate, Duffy binding protein region II
81 (DBPII). The experimental approach included retrospectively analyzing the relationship between the
82 long-term antibody response to DBPII-related antigens in the presence (or absence) of a sustained
83 response to EBV, as determined by the detection of circulating EBV DNA (EBV-DNAemia) or
84 EBV-specific antibody responses to the viral capsid antigen P18 (VCAp18) or EBV nuclear antigen
85 1 (EBNA1).

86

87 **Material and methods**

88 **Area and study population**

89 The study was carried out in the agricultural settlement of Rio Pardo (1°46'S—1°54'S, 60°
90 22'W—60°10'W), Presidente Figueiredo municipality, Northeast of Amazonas State in the
91 Brazilian Amazon region (Fig 1A). The study site and malaria transmission patterns were described
92 in detail elsewhere [16-18]. In this area, malaria transmission is considered hypo to mesoendemic,
93 and most residents were natives of the Amazon region. Inhabitants of the settlement live on
94 subsistence farming and fishing along the small streams. In the study area, *P. vivax* transmission is
95 predominant over *P. falciparum* (Fig 1B) and, since 2010, *P. vivax* has been responsible for all
96 clinical cases of malaria. Malaria transmission decreased drastically in recent years, and as of 2020,
97 no new clinical cases have been reported (Fig 1B).

98

99

100 **Fig 1. Study site and methodological approach according to the temporal distribution of**
101 **malaria cases during the 14-year follow up period (2008-2022).** A) The study site, Rio Pardo
102 settlement (dark green), in the Amazonas State (AM) of the Brazilian Amazon region (malaria-
103 endemic area, light green). B) Monthly-time series of malaria cases in the study area, including
104 periods of high (I and III, light grey) and low (II and IV, dark grey) malaria transmission. Malaria
105 cases (microscopy-positives) were reported by the Brazilian Epidemiological Surveillance System

106 for Malaria (SIVEP-Malaria), with *P. falciparum* (red) and *P. vivax* (blue) cases plotted per month.
107 C) Study design included nine cross-sectional surveys which were carried-out between 2008 and
108 2022. Number of participants enrolled per cross-sectional survey is shown inside the circles above
109 (cross-sectional, n), and number of eligible participants for the current study is inside the circles
110 below (eligible participants, n).

111

112 **Study design and cross-sectional surveys**

113 A population-based open cohort study was initiated in November 2008 and included three
114 cross-sectional surveys carried-out at six-month intervals (baseline, 6 and 12 months) as previously
115 reported [15, 16]. Briefly, (i) interviews were conducted through a structured questionnaire to obtain
116 demographical, epidemiological, and clinical data; (ii) physical examination, including body
117 temperature and spleen/liver size were recorded according to standard clinical protocols; (iii)
118 venous blood was collected from individuals aged five years or older (EDTA, 5 mL); and (iv)
119 examination of Giemsa-stained thick blood smears for the presence of malaria parasites by light
120 microscopy. The geographical location of each dwelling was recorded using a hand-held 12-channel
121 global positioning system (GPS) (Garmin 12XL, Olathe, KS, USA) with a positional accuracy of
122 within 15m. Additional cross-sectional surveys were conducted during the 6th to 14th years of the
123 study, specifically on the following dates: October 6–13, 2014 (6th year), July 6–11, 2015 (7th
124 year), July 18–27, 2017 (9th year), August 4–16, 2019 (11th year), November 28–December 10,
125 2021 (13th year), and June 6–16, 2022 (14th year). During the long-term follow up study, the
126 number of malaria cases fluctuated in the study area, reflecting period of high (I and III) and low (II
127 and IV) malaria transmission (Fig 1B). The current study involved a retrospective approach, and the
128 methodological strategy was designed to include samples from all nine cross-sectional surveys
129 without any new recruitment involved. For this, a database (EpiData software;
130 <http://www.epidata.dk>) contained all individual information was accessed between June 27 of 2022
131 until July 30, 2024; in the database individual data were not linked to participants' identity as
132 participants were assessed by codes. The non-eligible criteria were (i) refusal to sign the informed

133 consent; (ii) young children (<5 years); (iii) pregnant women; (iv) any other morbidity that could be
134 traced; (iv) individuals who were unable to be recruited during at least two cross-sectional surveys,
135 (iv) individuals whose biological samples (DNA and plasma) were unavailable. A total of 272
136 individuals were eligible to the current study (Table 1), and they matched the original population for
137 age, sex, malaria exposure [17]. The number of eligible participants selected per cross-sectional
138 surveys was included in the Fig 1C.

139

140 **Table 1. Demographic and epidemiological data of participants at the time of enrollment**

Variable	At enrollment (n=272)
Age, years - Median (IQR ¹)	35 (14-51)
Gender - male: female	1.12:1
Riverine population, n (%)	143 (53%)
Years of malaria exposure - Median (IQR ¹)	29 (15-48)
Years of residence in Rio Pardo - Median (IQR ¹)	19 (12-21)

141 ¹IQR, the Interquartile range

142

143 The ethical and methodological aspects of this study were approved by the Ethical
144 Committee of Research on Human Beings from the René Rachou Institute (CAAE:
145 96098618.9.0000.5091), according to the Resolutions of the Brazilian Council on Health (CNS-
146 196/96 and CNS-466/2012). Formal written consent was obtained from all participants, either from
147 the participants themselves, their next of kin, caregivers, or guardians on behalf of child
148 participants. Data are separated from personal identifiers through use of a code.

149 The current study was conducted according to Laboratory biosafety and biosecurity policy
150 guidelines of the Oswaldo Cruz Foundation (FIOCRUZ, Ministry of Health, Brazil
151 (http://www.fiocruz.br/biosseguranca/Bis/manuais/biosseg_manuais.html)).

152

153 **Laboratory diagnosis of malaria**

154 At the time of blood collection, all individuals were submitted to a finger-prick for malaria
155 diagnosis by light microscopy. The Giemsa-stained thick blood smears were prepared and examined
156 by experienced local microscopists, according to the malaria diagnosis guidelines of the Brazilian
157 Ministry of Health. Species-specific real-time PCR assay was conducted essentially as previously
158 described [19]. For this, genomic DNA was extracted from either whole blood samples collected in
159 EDTA, or from dried blood spots on filter paper using the Puregene blood core kit B (Qiagen,
160 Minneapolis, MN, USA) or the QIAmp DNA mini kit (Qiagen), respectively, according to
161 manufacturers' instructions.

162

163 **Recombinant blood stage *P. vivax* proteins and IgG antibodies** 164 **detection**

165 **DBPII-related antigens.** DBPII-Sal1, a recombinant Duffy binding protein region II
166 (DBPII) [20] including amino acids 243–573 of the Sal1 reference strain, and recombinant
167 DEKnull-2 [21], an engineered DBPII immunogen, were expressed as a 39kDa 6xHis fusion protein
168 and properly refolded, as previously described [21, 22]. Conventional Enzyme-Linked
169 Immunoassays (ELISA) for *P. vivax* IgG antibodies were carried out using *P. vivax* blood-stage
170 recombinant proteins as previously described [23], with serum samples at a dilution of 1:100.
171 Recombinant proteins were used at a final concentration of 3 µg/mL. The results were expressed as
172 ELISA reactivity index (RI), calculated as the ratio of the mean optical density (OD at 492 nm) of
173 each sample to the mean OD plus three standard deviations of negative control plasma samples
174 from 30 individuals living in a nonendemic area of malaria (Belo Horizonte, Minas Gerais, Brazil)
175 and who have never been exposed to malaria transmission (unexposed volunteers). Values of RI >
176 1.0 were considered seropositive.

177

178 **EBV DNA detection by real-time PCR**

179 The PCR primers for this assay were previously selected in the single-copy BALF-5 gene
180 encoding the viral DNA polymerase [24]; the upstream and downstream primer sequences were 50-
181 CGGAAGCCCTCTGGACTTC-30 and 50-CCCTGTTTATCCGATGGAATG-30, respectively, with
182 a fluorogenic probe (50-TGTACACGCACGAGAAATGCGCC-30) with a sequence located
183 between the PCR primers. Detectable DNA from EBV was identified by a real-time PCR assay as
184 previously described [15]. Briefly, DNA from whole blood samples collected in EDTA was
185 extracted using Puregene blood core kit B (Qiagen, Minneapolis, MN, USA). The PCR reaction was
186 performed using a mixture containing 1 μ L of DNA, 0.2 μ M each primer, 0.1 μ M fluorogenic probe,
187 and 5 μ L of TaqMan Master Mix (PE Applied Biosystems), and the PCR cycle was performed as
188 follows: 2 min at 50°C, 10 min at 95°C, and 40 cycles of 15 s at 95°C and 1 min at 60°C. The
189 TaqMan Master mix (PE Applied Biosystems) was used for all reactions. For all PCR analyses,
190 water was used as negative control, and DNA samples from individuals with history of
191 mononucleosis were used as positive control. Samples were defined as negative if the CT values
192 exceeded 40 cycles.

193

194 **EBV antigens and serostatus**

195 EBV-specific antibodies were detected using two synthetic peptides covering
196 immunodominant epitopes of the viral capsid antigen P18 (VCAp18 [BFRF3]) and EBV nuclear
197 antigen 1 (EBNA1 [BKRF1]) [25, 26]. Both synthetic peptides were provided by Dr. J. M.
198 Middeldorp (VU University Medical Center, Amsterdam, Netherland). For the assessment of the
199 levels of antibodies against lytic (VCAp18) and latent (EBNA1) EBV antigens, we used synthetic
200 peptide-based ELISA assays as previously described [15]. Briefly, each peptide was used at final
201 concentration of 1 μ g/mL with plasma samples diluted 1:100. IgG reactivities were determined using
202 commercial anti-human IgG secondary antibody conjugated to horseradish peroxidase (HRP)
203 (Sigma-Aldrich). For each experiment, plasma samples from subjects with or without a history of
204 mononucleosis infection who had previously been screened for the presence or absence of EBV-

205 specific antibodies were included as positive (EBV seropositive) or negative controls
206 (seronegative), respectively. All OD 450nm values were normalized by subtracting the value for
207 1:100-diluted EBV negative sera used in duplicate in each ELISA run. ELISA's cutoffs were
208 previously established as [15]: (i) 0.38 for VCA IgG (82% sensitivity; 83% specificity), (ii) 0.20 for
209 EBNA1 IgG (75% sensitivity; 100% specificity).

210

211 **Statistical analysis**

212 A database was created using EpiData software (<http://www.epidata.dk>). The graphics and
213 the statistical analyses were performed using GraphPad Prism version 9.5.0 - GraphPad Software
214 (La Jolla, California, USA) and Stata software version 12.0 - Stata Corp (College Station, Texas,
215 USA).

216 The Shapiro-Wilk test was performed to evaluate normality of variables. For the statistical
217 analyses, the antibody response was defined either as a continuous variable (the levels of antibody
218 response) or as a binary categorical variable (proportion of seropositive individuals); differences
219 between medians were tested by Mann-Whitney test or Kruskal-Wallis as appropriate; differences
220 in proportions were evaluated by chi-square test or Fisher's exact test, as appropriated. Spearman's
221 correlation matrices were used to nonparametric measure of rank correlation. For statistical
222 purposes, the amount of time participants contributed to this open cohort study was estimated in
223 persons-month, with the sum of total time contributed by all subjects (months) used to calculate the
224 incidence densities of the events of interest. Kaplan-Meier curves of survival were used to estimate
225 the probability of remaining seropositive for *P. vivax* as function of the profile of EBV infection
226 (serostatus and EBV-DNAemia). For that, the average duration of seropositivity over the 14th-years
227 period was defined when 50% of responders lost their antibodies. Logistical regression models were
228 constructed to investigate *P. vivax* antibodies clearance (rates adjusted per 100 persons-month)
229 according to the profile of EBV infections, with the relative risk (95% CI) of losing *P. vivax*

230 antibody response estimated according to the first seronegative episode. For all analyses, an alpha
231 error of 0.05 was considered.

232

233 **Results**

234 ***Plasmodium vivax* infections and circulating EBV DNA during** 235 **the follow-up**

236 In this long-term follow-up study, malaria blood-stage infections varied significantly, but
237 with a predominance of sub-patent (PCR-positive) over patent (microscopy-positive) infections (Fig
238 2A). All malaria infections detected by microscopy were identified as *P. vivax* mono-infections,
239 with all but one (11 of 12) detected during the first year of the follow-up (Period I). Submicroscopic
240 malaria infections were also predominant in the first year of follow-up, with frequency ranging
241 from 9 to 22% (Fig 2A). In subsequent cross-sectional surveys, lower frequencies of PCR-positive
242 samples were detected (3-4% and 4-6% during periods II and III, respectively), with no cases of
243 malaria detected at the end of the study (IV) (Fig 2A). Considering all malaria cases detected during
244 the study (n=113), there was a predominance of *P. vivax* mono-infection, accounting for 76%
245 (n=86) of the total malaria infections, compared to 12% (n=14) of *P. falciparum*, and 12% (n=13) of
246 mixed infections by these two *Plasmodium* species (S1 Fig).

247

248

249 **Fig 2. Malaria infections and EBV-DNAemia during the follow-up-period.** A) Frequencies of
250 malaria positive samples detected by microscopy (red bars) or species-specific PCR-based protocol
251 (light pink bars) and B) Frequencies of circulating EBV DNA (EBV-DNAemia) detected by virus-
252 specific PCR-based protocol (lilac bars). Each bar represents a cross-sectional survey, with dashed
253 lines representing the periods of high (I and III) and low (II and IV) malaria transmission, as
254 described in the legend of Fig 1B. C) A comparison between the proportion of malaria infections
255 and EBV-DNAemia over time. D) Representation of a Spearman correlation coefficient, in which
256 each dot represents the intersection between the frequency of malaria infections and detectable

257 EBV-DNAemia by cross-sectional survey. Numbers at the bottom of each bar (A, B) represent the
258 number of participants per survey (n survey) and the total number of participants per period (n
259 period).

260

261

262 On the first period of follow-up, the proportion of individuals who had circulating viral
263 DNA (EBV-DNAemia) ranged from 28 to 37% (Fig 2B). After that, EBV-DNAemia episodes
264 decreased substantially (Fig 1C), except for the beginning of period III (9-years of the follow-up), a
265 time of high malaria transmission in the study area (Fig 1B). It is noteworthy that the lowest
266 frequencies of EBV DNA positivity were found during the II (11 to 14%) and IV (2 to 3%) periods
267 of the study (Fig 2B), corresponding to periods of lowest malaria transmission in the area (Fig 1B).

268 In the study population, episodes of EBV-DNAemia were transiently detected in most individuals,
269 which excluded the possibility of categorizing individuals as having long-term persistent EBV-
270 DNAemia. Only seven out of 272 individuals had long-term EBV-DNAemia (positive samples from
271 baseline to at least the II period); four of them (343, 272, 179, 276) had malaria infections at some
272 point in the study (S1 Fig). During the follow-up, a strong positive association was detected
273 between malaria infections and EBV-DNAemia ($r = 0.7269$; $p = 0.0035$) (Fig 2D). Similar results
274 were found when only *P. vivax* mono-infections were analyzed ($r = 0.6522$; $p = 0.0085$, data not
275 shown).

276

277 **Episodes of EBV-DNAemia and longevity of naturally acquired antibodies** 278 **against *Plasmodium vivax***

279 In the study population, the profile of antibody response to DBPII-based antigens decreased
280 over time, with a more prolonged response to DEKnull-2 in period II (low transmission) as
281 compared with DBPII (Sal1) (S2 Fig); at the same time, the levels of anti-DBPII antibodies were
282 lower than anti-DEKnull-2. To further evaluate whether episodes of EBV-DNAemia (none, one, or
283 multiple) could influence the persistence of strain-specific (Sal1) or strain-transcending (DEKnull-

284 2) DBPPII antibody repertoire, Kaplan-Meier's survival curves were constructed. In general, the
285 results demonstrated that the persistence of antibody responses to either DBPPII-Sal1 or DEKnull-2
286 was similar between individuals who had none, one or multiple episodes of EBV-DNAemia (Fig 3).
287 More specifically, considering the subgroups of DBPPII-Sal1 responders, the average time in which
288 50% of responders lost their antibody response ranges from 156 to 168 months (S1 Table). The
289 average time for DEKnull-2 subgroups to lose antibody response was estimated as 168 months. In
290 addition, antibody clearance rates (adjusted per 100 persons-month) were similar between
291 subgroups of DBPPII-Sal1 (0.48 to 0.57) and DEKnull-2 (0.27 to 0.46) (S1Table).

292

293

294 **Fig 3. Maintenance of *P. vivax* antibody response over time according to episodes of EBV-**
295 **DNAemia (none, one or multiple).** The Kaplan-Meier's curves show the cumulative survival
296 probabilities of maintaining an antibody response against (A) DBPPII-Sal1 and (B) DEKnull-2
297 among responders who were stratified according to the presence or absence of detectable EBV-
298 DNAemia. Each line represents the survival probability of antibodies over time among (i)
299 individuals who did not have detectable EBV DNA episodes during the 14-years follow-up (dashed
300 line); (ii) individuals who had a single EBV DNA episode (lilac line); and (iii) individuals who had
301 more than one (multiple) EBV DNA episodes (purple line). Number of individuals and contribution
302 time (persons/month) of each group were described in S1 Table.

303

304

305 **EBV serostatus and long-term *P. vivax* antibody response**

306 To evaluate the EBV serological status of the study population, the presence and levels of
307 IgG antibodies to EBV antigens associated with lytic (VCAp18) or latent (EBNA1) phases of
308 infection were investigated. As expected for a predominantly adult population, responders'
309 frequencies were high (> 60%) for both viral proteins and it remained relatively stable until the end
310 of the follow-up (S3 Fig). In general, IgG-VCAp18 levels were higher compared to IgG-EBNA1.

311 Spearman correlation analyses were performed to investigate whether the levels of EBV
312 antibodies correlated with *P. vivax*-specific antibodies. Regardless of the malaria transmission
313 period (high, I/III or low, II/IV), the results demonstrated that anti-EBV antibodies (VCAp18 and
314 EBNA1) did not correlate with anti-*P. vivax* antibodies (DBP11-Sal1 and DEKnull-2) (Fig 4).
315 Despite of that, the antibody responses to DBP11-Sal1 and DEKnull-2 were strongly correlated
316 ($r=0.71$ to 0.82 ; $p<0,0001$ for all periods). In general, antibodies to VCAp18 and EBNA1 presented
317 a weak but positive correlation (except for period IV).

318

319

320 **Fig 4. Correlation between IgG antibody levels to *Plasmodium vivax* and EBV virus over**
321 **time.** Clustering was based on the Spearman correlation coefficient for assays measuring specific
322 EBV antibodies (VCAp18 and EBNA1) and specific *P. vivax* antibodies (DBP11-Sal1 and DEKnull-
323 2). Matrix heatmaps were illustrated for each study period (I, II, III and IV). Positive correlations
324 are shown in blue and negative correlations are shown in red. The asterisks represent statistically
325 significant differences (* $p < 0,05$; ** $p < 0,01$; *** $p < 0,001$).

326

327 To determine whether EBV serological status could influence the long-term antibody
328 response to DBP11-based antigens, IgG-VCAp18 and IgG-EBNA1 carriers were stratified as
329 persistent (PR), temporary (TR) or non-responder (NR). Survival curves of antibodies allowed to
330 demonstrate that the decline over time of responders to both DBP11-based antigens were similar
331 between PR, TR or NR for either VCAp18 (Figs 5A and 5B) or EBNA1 (Figs 5C and 5D). Despite
332 that, antibody clearance rates for DEKnull-2 responders (0.26 to 0.36 per 100 persons-month)
333 declined more slowly than from DBP11-Sal1 (0.45 to 0.53 per 100 persons-months) (S1 Table).

334

335

336 **Fig 5. Maintenance of *P. vivax* antibody response over time according to EBV serostatus**
337 **(persistent-PR, temporary-TR, and non-responder-NR).** The Kaplan-Meier's curves show the
338 cumulative survival probabilities of maintaining an antibody response against (A, C) DBP11-Sal1
339 and (B, D) DEKnull-2 among responders who were stratified according to the response profile for

340 VCAp18 or EBNA1. Each line represents the survival probability of antibodies over time among (i)
341 persistent responders, who had IgG response over the 14 years of follow-up (A and B - brown line;
342 C and D - red line); (ii) temporary responders, who had variable IgG response during cross-
343 sectional surveys (A and B - yellow line; C and D - pink line); and (iii) non-responders, who had no
344 IgG response detected any time in the study (dashed line). Number of individuals and contribution
345 time (person/month) of each group are described in S1 Table.

346

347

348 **Discussion**

349 This 14-year follow-up study provided for the first time an exploratory description of the
350 long-term *P. vivax* humoral immune response in the context of EBV co-infection. For this,
351 immunogens based on the DBPII were used, including a common DBPII variant (Sal1) circulating
352 in the Amazon area [16] and the engineered DEKnull-2 that has been associated with stronger,
353 broader, and long-term neutralizing antibody response in the study area [18, 21].

354 In the study population, it was essential to identify viral DNA carriers, as circulating EBV
355 DNA could be an indicator of active EBV replication [27]. In this *P. vivax* semi-immune adults, the
356 detection of EBV DNA in peripheral blood decreased significantly over the years, precluding any
357 attempts to classify individuals as long-term DNAemia carriers. The detection of viral DNA of most
358 carriers did not persist over the first few months of the study, which may reflect that once infected
359 by EBV early on, the subjects - in general - have good immunological control over EBV (reflected
360 here by stable antibody responses to VCAp18 and EBNA1). Concomitantly, acute malaria infection
361 (presence of parasites and/or *P. vivax* DNA in the peripheral blood) also decreased over time, which
362 led to a positive association between the presence of acute *P. vivax* infection and EBV-DNAemia.
363 At this point, it is not possible to determine whether this potential association represents a spurious
364 correlation or may reflect an influence of concurrent *P. vivax* parasite in the activation of EBV
365 replication cycle, as it has been proposed in the case of the more lethal malaria parasite, *P.*
366 *falciparum* [28]. In Indonesia, where *P. falciparum* and *P. vivax* species are co-endemic at

367 substantial proportions, it was demonstrated that EBV DNA levels were significantly elevated in
368 both *P. falciparum* and *P. vivax* mono-infections as compared with uninfected controls, suggesting
369 cytokine-mediated imbalance of immune control of EBV during active malaria [29]. Although the
370 study from Indonesia supports our findings, the influence of concomitant transmission of *P.*
371 *falciparum* cannot be ruled out in that area, especially because PCR-based protocols were not used
372 to investigate submicroscopic infections. In the case of *P. falciparum* – whose relationship with
373 EBV infections is involved in the genesis of endemic Burkitt lymphoma (eBL) [30] – it was
374 demonstrated that repeated malaria infections were associated with increased proliferation and
375 transformation of EBV-infected cells [31]. Also, the clearance of circulating EBV after *P.*
376 *falciparum* antimalarial treatment suggests a direct relationship between active malaria infection
377 and viral reactivation [28]. Of note, however, the aggressive eBL childhood cancer seems to be
378 exclusively linked to *P. falciparum* exposure, but not to other human malaria parasites [32].
379 Because of this, the direct relationship between active *P. vivax* infection and viral reactivation needs
380 further confirmation.

381 We further analyzed whether one or more episodes of viral DNAemia, at any time of the
382 long-term follow-up period, could impact the persistence of *P. vivax*-specific antibody responses.
383 Regardless of viral DNA carriers' status, maintenance over time of antibody responses to either
384 DBPII-Sal1 or DEKnull-2 was similar between individuals who had no, one or multiple episodes of
385 EBV-DNAemia; for example, the average time for the loss of antibody response was 168 months
386 for DEKnull-2 and from 156 to 168 months for DBPII-Sal1. In our previous case-control study,
387 lower IgG reactivity to *P. vivax* antigens was detected in the group of persistent EBV DNA carriers
388 (cases) compared to age-matched controls (no circulant viral DNA) [15]. Unfortunately, differences
389 in the study design and the absence of a subset of persistent viral DNA carriers in the current study
390 preclude a direct comparison with the previous result. Despite this, it must be noted that, in the
391 present study, the frequencies of both malaria infection and circulating viral DNA progressively
392 decreased over time, making it reasonable to speculate that this may have masked a possible

393 influence of active EBV replication on the long-term *P. vivax* immune response. To properly address
394 this topic, it would be of relevance to examine *P. vivax*-exposed children, as typically the EBV
395 primary infection occurs during childhood, with an early EBV seroconversion in Latin American
396 populations associated with low socioeconomic status [33].

397 To address whether EBV serostatus could influence acquired *P. vivax* antibody responses,
398 individuals were further categorized as persistent (PR), temporary (TR), or non-responder (NR) for
399 lytic (VCAp18) or latent (EBNA1) viral antigens. Although antibody clearance rates were faster for
400 Sal-1 (0.49 to 0.55/100 persons-month) than for DEKnull-2 (0.27 to 0.37/100 persons-month), the
401 results of the 14-year follow-up study demonstrated that probabilities of maintaining antibodies to
402 DBP-II-based antigens were similar for IgG-VCAp18 or IgG-EBNA1 subgroups (PR, TR, or NR). It
403 is noteworthy that no association (positive or negative) was detected between the levels of anti-EBV
404 antibodies and anti-*P. vivax* antibodies. Together, these results suggested that sustained EBV
405 antibody responses to lytic/latent viral antigens did not impair the long-term antibody response to
406 DBP-II-related antigens, including both strain-specific (Sal1) and strain-transcending (DEKnull-2)
407 immune responses.

408 Our study has limitations that should be considered when interpreting the results. First, a
409 progressive decrease in malaria transmission over time precluded more robust statistical analysis to
410 confirm the association between acute *P. vivax* infection and EBV-DNAemia. To explore whether
411 concurrent *P. vivax* infection may result in EBV lytic replication, perhaps it should be more
412 appropriate to evaluate the levels of viral DNA methylation, as unmethylated viral DNA occurs
413 when EBV switches to the lytic phase and in virions [34]; nevertheless, the investigation of this
414 topic was outside of the scope of the current study. Secondly, the EBV serostatus of the study
415 population was constrained to the profile of IgG antibodies to VCAp18 (lytic) and EBNA1 (latent)
416 antigens. Due to the limitations of plasma samples available over the 14 years of study, we chose
417 the lytic antigen VCAp18, because from a panel of synthetic peptides targeting the most frequent
418 EBV lytic antigens (i.e., IgG/IgM to VCAp18, IgM to ZEBRA and IgM EAd-p45/52), only the

419 levels of anti-IgG VCAp18 showed a positive association with EBV DNA copies in the peripheral
420 blood of Amazonian adults [15]. Notwithstanding these limitations, we are confident that, in this
421 immunocompetent adult population, the assessment of VCAp18-IgG and EBNA1-IgG represented
422 the best combination for long-term sero-detection of anti-EBV antibodies. Finally, as EBV latency
423 establishment is in B cells [35], it should be of interest to investigate whether *P. vivax*-specific
424 memory B cells are compromised during EBV reactivation.

425 In conclusion, in this 14-year follow-up study we demonstrate that, in an immunocompetent
426 *P. vivax*-exposed adult population, neither sporadic episodes of circulating EBV DNA nor a
427 sustained antibody response to lytic/latent EBV antigens influence the longevity of both strain-
428 specific and strain-transcending DBPII immune responses. Future studies should investigate a
429 possible association between the presence of acute *P. vivax* infection and EBV-DNAemia.

430

431 **Acknowledgments**

432 We thank the inhabitants of Rio Pardo for enthusiastic participation in the study; the local
433 malaria control team in Presidente Figueiredo for their logistic support; the Instituto Leônidas &
434 Maria Deane – Fiocruz-Amazônia and Fundação de Medicina Tropical Dr. Heitor Vieira Dourado
435 for local support, and the Instituto René Rachou – Fiocruz-Minas, Belo Horizonte, MG, for overall
436 support. LHC, FSK, and CFJF are research fellows from CNPq. Scholarship was sponsored by
437 FAPEMIG (BAR), CAPES (LFFG and SLA) and the Fiocruz Innovation Support Initiative/Inova-
438 Fiocruz (MFAN). We also thank the financial support from the Program for Institutional
439 Internationalization of the Higher Education Institutions and Research Institutions of Brazil-
440 CAPES-PrInt from FIOCRUZ. The authors thank the Network Technological Platforms from
441 FIOCRUZ, for the support and financing of the services provided by Digital and Real-Time PCR
442 Facility from René Rachou Institute - FIOCRUZ MG - RPT09D.

443

444 **References**

445

- 446 1. Weiss DJ, Lucas TCD, Nguyen M, Nandi AK, Bisanzio D, Battle KE, et al. Mapping the
447 global prevalence, incidence, and mortality of *Plasmodium falciparum*, 2000-17: a spatial and
448 temporal modelling study. *Lancet*. 2019;394(10195):322-31. Epub 20190619. doi: 10.1016/S0140-
449 6736(19)31097-9. PubMed PMID: 31229234; PubMed Central PMCID: PMC6675740.
- 450 2. Battle KE, Lucas TCD, Nguyen M, Howes RE, Nandi AK, Twohig KA, et al. Mapping the
451 global endemicity and clinical burden of *Plasmodium vivax*, 2000-17: a spatial and temporal
452 modelling study. *Lancet*. 2019;394(10195):332-43. Epub 20190619. doi: 10.1016/S0140-
453 6736(19)31096-7. PubMed PMID: 31229233; PubMed Central PMCID: PMC6675736.
- 454 3. Fernandez-Becerra C, Aparici-Herraiz I, Del Portillo HA. Cryptic erythrocytic infections in
455 *Plasmodium vivax*, another challenge to its elimination. *Parasitol Int*. 2022;87:102527. Epub
456 20211209. doi: 10.1016/j.parint.2021.102527. PubMed PMID: 34896615.
- 457 4. Anstey NM, Tham WH, Shanks GD, Poespoprodjo JR, Russell BM, Kho S. The biology and
458 pathogenesis of *vivax* malaria. *Trends Parasitol*. 2024;40(7):573-90. Epub 20240515. doi:
459 10.1016/j.pt.2024.04.015. PubMed PMID: 38749866.
- 460 5. Price RN, Commons RJ, Battle KE, Thriemer K, Mendis K. *Plasmodium vivax* in the Era of
461 the Shrinking *P. falciparum* Map. *Trends Parasitol*. 2020;36(6):560-70. Epub 20200422. doi:
462 10.1016/j.pt.2020.03.009. PubMed PMID: 32407682; PubMed Central PMCID:
463 PMC67297627.
- 464 6. Mendonca VR, Andrade BB, Souza LC, Magalhaes BM, Mourao MP, Lacerda MV, et al.
465 Unravelling the patterns of host immune responses in *Plasmodium vivax* malaria and dengue co-
466 infection. *Malar J*. 2015;14:315. Epub 20150814. doi: 10.1186/s12936-015-0835-8. PubMed PMID:
467 26271921; PubMed Central PMCID: PMC4536664.
- 468 7. Rattanapunya S, Kuesap J, Chaijaroenkul W, Rueangweerayut R, Na-Bangchang K.
469 Prevalence of malaria and HIV coinfection and influence of HIV infection on malaria disease
470 severity in population residing in malaria endemic area along the Thai-Myanmar border. *Acta Trop*.
471 2015;145:55-60. Epub 20150226. doi: 10.1016/j.actatropica.2015.02.001. PubMed PMID:
472 25728746.
- 473 8. Hussein R, Guedes M, Ibraheim N, Ali MM, El-Tahir A, Allam N, et al. Impact of COVID-
474 19 and malaria coinfection on clinical outcomes: a retrospective cohort study. *Clin Microbiol Infect*.

475 2022;28(8):1152 e1- e6. Epub 20220331. doi: 10.1016/j.cmi.2022.03.028. PubMed PMID:
476 35367364; PubMed Central PMCID: PMCPMC8968160.

477 9. Forero-Pena DA, Carrion-Nessi FS, Omana-Avila OD, Mendoza-Millan DL, Romero SR,
478 Escalante-Perez IA, et al. Plasmodium vivax and SARS-CoV-2 co-infection in Venezuela: A case
479 series from the malaria hotspot in Latin America. *Travel Med Infect Dis.* 2022;50:102460. Epub
480 20220914. doi: 10.1016/j.tmaid.2022.102460. PubMed PMID: 36115526; PubMed Central PMCID:
481 PMCPMC9473143.

482 10. Guerra CVC, da Silva BM, Muller P, Baia-da-Silva DC, Moura MAS, Araujo JDA, et al.
483 HIV infection increases the risk of acquiring Plasmodium vivax malaria: a 4-year cohort study in
484 the Brazilian Amazon HIV and risk of vivax malaria. *Sci Rep.* 2022;12(1):9076. Epub 20220531.
485 doi: 10.1038/s41598-022-13256-4. PubMed PMID: 35641592; PubMed Central PMCID:
486 PMCPMC9156757.

487 11. Forero-Pena DA, Carrion-Nessi FS, Lopez-Perez M, Sandoval-de Mora M, Amaya ID,
488 Gamardo AF, et al. Seroprevalence of viral and bacterial pathogens among malaria patients in an
489 endemic area of southern Venezuela. *Infect Dis Poverty.* 2023;12(1):33. Epub 20230410. doi:
490 10.1186/s40249-023-01089-w. PubMed PMID: 37038195; PubMed Central PMCID:
491 PMCPMC10084699.

492 12. da Veiga GTS, Moriggi MR, Vettorazzi JF, Muller-Santos M, Albrecht L. Plasmodium vivax
493 vaccine: What is the best way to go? *Front Immunol.* 2022;13:910236. Epub 20230116. doi:
494 10.3389/fimmu.2022.910236. PubMed PMID: 36726991; PubMed Central PMCID:
495 PMCPMC9885200.

496 13. Matar CG, Jacobs NT, Speck SH, Lamb TJ, Moormann AM. Does EBV alter the
497 pathogenesis of malaria? *Parasite Immunol.* 2015;37(9):433-45. Epub 2015/06/30. doi:
498 10.1111/pim.12212. PubMed PMID: 26121587.

499 14. Thorley-Lawson DA. Epstein-Barr virus: exploiting the immune system. *Nat Rev Immunol.*
500 2001;1(1):75-82. doi: 10.1038/35095584. PubMed PMID: 11905817.

501 15. Dias MHF, Guimaraes LFF, Barcelos MG, Moreira EUM, do Nascimento MFA, de Souza
502 TN, et al. Impact of Epstein-Barr virus co-infection on natural acquired Plasmodium vivax antibody
503 response. *PLoS Negl Trop Dis.* 2022;16(8):e0010305. Epub 20220803. doi:
504 10.1371/journal.pntd.0010305. PubMed PMID: 35921373; PubMed Central PMCID:
505 PMCPMC9377613.

- 506 16. Kano FS, Sanchez BA, Sousa TN, Tang ML, Saliba J, Oliveira FM, et al. Plasmodium vivax
507 Duffy binding protein: baseline antibody responses and parasite polymorphisms in a well-
508 consolidated settlement of the Amazon Region. Trop Med Int Health. 2012;17(8):989-1000. Epub
509 2012/05/31. doi: 10.1111/j.1365-3156.2012.03016.x. PubMed PMID: 22643072.
- 510 17. Kano FS, Souza-Silva FA, Torres LM, Lima BA, Sousa TN, Alves JR, et al. The Presence,
511 Persistence and Functional Properties of Plasmodium vivax Duffy Binding Protein II Antibodies
512 Are Influenced by HLA Class II Allelic Variants. PLoS Negl Trop Dis. 2016;10(12):e0005177.
513 Epub 2016/12/14. doi: 10.1371/journal.pntd.0005177. PubMed PMID: 27959918; PubMed Central
514 PMCID: PMC5154503.
- 515 18. Medeiros CMP, Moreira EUM, Pires CV, Torres LM, Guimaraes LFF, Alves JRS, et al.
516 Dynamics of IgM and IgG responses to the next generation of engineered Duffy binding protein II
517 immunogen: Strain-specific and strain-transcending immune responses over a nine-year period.
518 PLoS One. 2020;15(5):e0232786. Epub 2020/05/08. doi: 10.1371/journal.pone.0232786. PubMed
519 PMID: 32379804; PubMed Central PMCID: PMC7205269.
- 520 19. Amaral LC, Robortella DR, Guimaraes LFF, Limongi JE, Fontes CJF, Pereira DB, et al.
521 Ribosomal and non-ribosomal PCR targets for the detection of low-density and mixed malaria
522 infections. Malar J. 2019;18(1):154. Epub 2019/05/02. doi: 10.1186/s12936-019-2781-3. PubMed
523 PMID: 31039781; PubMed Central PMCID: PMC6492410.
- 524 20. Fang XD, Kaslow DC, Adams JH, Miller LH. Cloning of the Plasmodium vivax Duffy
525 receptor. Mol Biochem Parasitol. 1991;44(1):125-32. Epub 1991/01/01. doi: 10.1016/0166-
526 6851(91)90228-x. PubMed PMID: 1849231.
- 527 21. Ntumngia FB, Pires CV, Barnes SJ, George MT, Thomson-Luque R, Kano FS, et al. An
528 engineered vaccine of the Plasmodium vivax Duffy binding protein enhances induction of broadly
529 neutralizing antibodies. Sci Rep. 2017;7(1):13779. Epub 2017/10/25. doi: 10.1038/s41598-017-
530 13891-2. PubMed PMID: 29062081; PubMed Central PMCID: PMC5653783.
- 531 22. Ntumngia FB, Adams JH. Design and immunogenicity of a novel synthetic antigen based on
532 the ligand domain of the Plasmodium vivax duffy binding protein. Clin Vaccine Immunol.
533 2012;19(1):30-6. Epub 2011/11/26. doi: 10.1128/CVI.05466-11. PubMed PMID: 22116684;
534 PubMed Central PMCID: PMC3255949.
- 535 23. Pires CV, Alves JRS, Lima BAS, Paula RB, Costa HL, Torres LM, et al. Blood-stage
536 Plasmodium vivax antibody dynamics in a low transmission setting: A nine year follow-up study in

- 537 the Amazon region. PLoS One. 2018;13(11):e0207244. Epub 2018/11/13. doi:
538 10.1371/journal.pone.0207244. PubMed PMID: 30419071; PubMed Central PMCID:
539 PMCPMC6231651.
- 540 24. Kimura H, Morita M, Yabuta Y, Kuzushima K, Kato K, Kojima S, et al. Quantitative
541 analysis of Epstein-Barr virus load by using a real-time PCR assay. J Clin Microbiol.
542 1999;37(1):132-6. Epub 1998/12/17. doi: 10.1128/JCM.37.1.132-136.1999. PubMed PMID:
543 9854077; PubMed Central PMCID: PMCPMC84187.
- 544 25. Fachiroh J, Paramita DK, Hariwiyanto B, Harijadi A, Dahlia HL, Indrasari SR, et al. Single-
545 assay combination of Epstein-Barr Virus (EBV) EBNA1- and viral capsid antigen-p18-derived
546 synthetic peptides for measuring anti-EBV immunoglobulin G (IgG) and IgA antibody levels in sera
547 from nasopharyngeal carcinoma patients: options for field screening. J Clin Microbiol.
548 2006;44(4):1459-67. Epub 2006/04/07. doi: 10.1128/JCM.44.4.1459-1467.2006. PubMed PMID:
549 16597877; PubMed Central PMCID: PMCPMC1448657.
- 550 26. Piriou E, Kimmel R, Chelimo K, Middeldorp JM, Odada PS, Ploutz-Snyder R, et al.
551 Serological evidence for long-term Epstein-Barr virus reactivation in children living in a
552 holoendemic malaria region of Kenya. J Med Virol. 2009;81(6):1088-93. Epub 2009/04/22. doi:
553 10.1002/jmv.21485. PubMed PMID: 19382256; PubMed Central PMCID: PMCPMC3134942.
- 554 27. Rasti N, Falk KI, Donati D, Gyan BA, Goka BQ, Troye-Blomberg M, et al. Circulating
555 epstein-barr virus in children living in malaria-endemic areas. Scand J Immunol. 2005;61(5):461-5.
556 doi: 10.1111/j.1365-3083.2005.01589.x. PubMed PMID: 15882438.
- 557 28. Donati D, Espmark E, Kironde F, Mbidde EK, Kanya M, Lundkvist A, et al. Clearance of
558 circulating Epstein-Barr virus DNA in children with acute malaria after antimalaria treatment. J
559 Infect Dis. 2006;193(7):971-7. Epub 20060301. doi: 10.1086/500839. PubMed PMID: 16518759.
- 560 29. Budiningsih I, Dachlan YP, Hadi U, Middeldorp JM. Quantitative cytokine level of TNF-
561 alpha, IFN-gamma, IL-10, TGF-beta and circulating Epstein-Barr virus DNA load in individuals
562 with acute Malaria due to *P. falciparum* or *P. vivax* or double infection in a Malaria endemic region
563 in Indonesia. PLoS One. 2021;16(12):e0261923. Epub 20211228. doi:
564 10.1371/journal.pone.0261923. PubMed PMID: 34962938; PubMed Central PMCID:
565 PMCPMC8714090.
- 566 30. Moormann AM, Bailey JA. Malaria - how this parasitic infection aids and abets EBV-
567 associated Burkitt lymphomagenesis. Curr Opin Virol. 2016;20:78-84. Epub 2016/10/01. doi:

568 10.1016/j.coviro.2016.09.006. PubMed PMID: 27689909; PubMed Central PMCID:
569 PMCPMC5102755.

570 31. Moormann AM, Chelimo K, Sumba OP, Lutzke ML, Ploutz-Snyder R, Newton D, et al.
571 Exposure to holoendemic malaria results in elevated Epstein-Barr virus loads in children. *J Infect*
572 *Dis.* 2005;191(8):1233-8. Epub 2005/03/19. doi: 10.1086/428910. PubMed PMID: 15776368.

573 32. Quintana MDP, Smith-Togobo C, Moormann A, Hviid L. Endemic Burkitt lymphoma - an
574 aggressive childhood cancer linked to Plasmodium falciparum exposure, but not to exposure to
575 other malaria parasites. *APMIS.* 2020;128(2):129-35. Epub 2020/03/07. doi: 10.1111/apm.13018.
576 PubMed PMID: 32133709.

577 33. Chabay P, Lens D, Hassan R, Rodriguez Pinilla SM, Valvert Gamboa F, Rivera I, et al.
578 Lymphotropic Viruses EBV, KSHV and HTLV in Latin America: Epidemiology and Associated
579 Malignancies. A Literature-Based Study by the RIAL-CYTED. *Cancers (Basel).* 2020;12(8). Epub
580 20200804. doi: 10.3390/cancers12082166. PubMed PMID: 32759793; PubMed Central PMCID:
581 PMCPMC7464376.

582 34. Guo R, Gewurz BE. Epigenetic control of the Epstein-Barr lifecycle. *Curr Opin Virol.*
583 2022;52:78-88. Epub 20211208. doi: 10.1016/j.coviro.2021.11.013. PubMed PMID: 34891084;
584 PubMed Central PMCID: PMCPMC9112224.

585 35. Thorley-Lawson DA, Hawkins JB, Tracy SI, Shapiro M. The pathogenesis of Epstein-Barr
586 virus persistent infection. *Curr Opin Virol.* 2013;3(3):227-32. Epub 20130515. doi:
587 10.1016/j.coviro.2013.04.005. PubMed PMID: 23683686; PubMed Central PMCID:
588 PMCPMC3789532.

589

590

591 **Supporting information**

592 **S1 Fig. Malaria infections in 77 eligible participants screened for the presence of circulating**
593 **EBV DNA during the follow-up study.** *P. vivax* infections are represented in red, *P. falciparum* in
594 yellow, mixed infections (*P. falciparum* plus *P. vivax*) in orange, and uninfected samples in white.
595 During the cross-sectional surveys, the presence or absence of episodes of EBV-DNAemia are
596 represented in purple and white circles, respectively.

597

598 **S2 Fig. Dynamics of naturally acquired antibody responses to *P. vivax* DBP_{II}-based antigens**

599 **during the follow-up study.** (A) Frequencies and (B) levels of antibodies against DBP_{II}-Sal1 and

600 DEKnull-2, as determined by conventional serological assays (ELISA). Results were expressed as

601 reactivity index (RI), with RI >1.0 considered as an ELISA-positive response. In B, black lines

602 inside the violin plot represent the median RI, with light green and blue lines representing the

603 interquartile range.

604

605 **S3 Fig. Dynamic of antibody responses to EBV peptides during the 14 years follow-up study.**

606 (A) Frequencies and (B) levels of antibodies against VCAp18 and EBNA1, as determined by

607 conventional serological assays (ELISA). Results were expressed as the optical density at 450 nm

608 (OD₄₅₀), with OD >0.37 and >0.20 considered as ELISA-positive responses to VCAp18 and

609 EBNA1, respectively. In B, black lines inside the violin plot represent the median RI, with yellow

610 and pink lines representing the interquartile range.

611

612 **S1 Table. DBP_{II}-related antibody responses over time based on the presence or absence of**

613 **EBV-DNAemia.**

614

615 **S2 Table. DBP_{II}-related antibody responses over time based on the antibody response profile**

616 **against EBV peptides**

617